In simple terms, drug development is a stepwise process to ensure that innovative products deliver safe and effective therapies. A necessary component of this process is bioanalytical method development and subsequent method validation. These crucial elements generate decision-informing data for regulatory assessment of safety and efficacy.
However, the complexity of biologic systems requires intricate bioanalytical approaches that are anything but simple. It requires a different sort of innovative thinking to ensure that a novel product is appropriately and sufficiently assessed to determine the safety and efficacy. Bioanalytical contract research organizations (CROs) work diligently to help sponsors minimize risk and maximize return so patients ultimately benefit.
